These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 17530024

  • 1. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies.
    Leonard JP, Goldenberg DM.
    Oncogene; 2007 May 28; 26(25):3704-13. PubMed ID: 17530024
    [Abstract] [Full Text] [Related]

  • 2. Epratuzumab: targeting B-cell malignancies through CD22.
    Coleman M, Goldenberg DM, Siegel AB, Ketas JC, Ashe M, Fiore JM, Leonard JP.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3991S-4S. PubMed ID: 14506198
    [Abstract] [Full Text] [Related]

  • 3. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
    Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, Feldman EJ, Ashe M, Schuster SJ, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Fields SZ, Cesano A, Goldenberg DM.
    Clin Cancer Res; 2004 Aug 15; 10(16):5327-34. PubMed ID: 15328168
    [Abstract] [Full Text] [Related]

  • 4. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.
    Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL, Engert A, Coiffier B, Hoelzer DF, Wegener WA, Teoh NK, Goldenberg DM, Lister TA.
    J Clin Oncol; 2006 Aug 20; 24(24):3880-6. PubMed ID: 16864854
    [Abstract] [Full Text] [Related]

  • 5. CD22 as a target of passive immunotherapy.
    Cesano A, Gayko U.
    Semin Oncol; 2003 Apr 20; 30(2):253-7. PubMed ID: 12720147
    [Abstract] [Full Text] [Related]

  • 6. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
    Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, Juan T, Talvenheimo J, Montestruque S, Sun J, Elliott G, Thomas J, Ferbas J, Kern B, Briddell R, Leonard JP, Cesano A.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3982S-90S. PubMed ID: 14506197
    [Abstract] [Full Text] [Related]

  • 7. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab).
    Mattes MJ, Sharkey RM, Karacay H, Czuczman MS, Goldenberg DM.
    Clin Cancer Res; 2008 Oct 01; 14(19):6154-60. PubMed ID: 18829494
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab.
    Carnahan J, Stein R, Qu Z, Hess K, Cesano A, Hansen HJ, Goldenberg DM.
    Mol Immunol; 2007 Feb 01; 44(6):1331-41. PubMed ID: 16814387
    [Abstract] [Full Text] [Related]

  • 10. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.
    Robak T.
    Curr Opin Investig Drugs; 2009 Jun 01; 10(6):588-96. PubMed ID: 19513948
    [Abstract] [Full Text] [Related]

  • 11. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
    DiJoseph JF, Dougher MM, Kalyandrug LB, Armellino DC, Boghaert ER, Hamann PR, Moran JK, Damle NK.
    Clin Cancer Res; 2006 Jan 01; 12(1):242-9. PubMed ID: 16397048
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
    Sharkey RM, Karacay H, Johnson CR, Litwin S, Rossi EA, McBride WJ, Chang CH, Goldenberg DM.
    J Nucl Med; 2009 Mar 01; 50(3):444-53. PubMed ID: 19223402
    [Abstract] [Full Text] [Related]

  • 15. Preclinical and phase I and II trials of rituximab.
    Maloney DG.
    Semin Oncol; 1999 Oct 01; 26(5 Suppl 14):74-8. PubMed ID: 10561021
    [Abstract] [Full Text] [Related]

  • 16. TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies.
    Robak T, Robak P, Smolewski P.
    Curr Opin Investig Drugs; 2009 Dec 01; 10(12):1383-90. PubMed ID: 19943209
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma.
    Martin P, Furman RR, Ruan J, Elstrom R, Barrientos J, Niesvizky R, Coleman M, Leonard JP.
    Semin Hematol; 2008 Apr 01; 45(2):126-32. PubMed ID: 18381108
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.